Schizophrenia Trial, Recruiting NCT05617898 Sponsor: University of Alabama at Birmingham Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT05617898
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 35 years old
  • People who have experienced their first episode of a psychotic illness that started within the last three years
  • People who have been diagnosed (using standard psychiatric guidelines called DSM-5) with schizophrenia, schizophreniform disorder, or schizoaffective disorder
  • People who are currently taking a type of antipsychotic medication known as a second-generation antipsychotic
  • People whose estimated pre-illness intellectual ability falls at or above a certain level, as measured by a standard reading test
  • People who are able to safely undergo brain scanning, meaning no pacemaker or metal implants in the body, and who are willing to be scanned
  • People who speak and understand English well enough to follow the testing instructions
  • People who have vision of at least 20/30, whether naturally or with corrective lenses

Who may not be able to join:

  • People where substance use makes it unclear whether the psychotic illness is the correct diagnosis (for example, if the psychosis may have been caused by drugs or alcohol)
  • People who have had a moderate or severe alcohol or drug use disorder in the past three months
  • People with a significant medical condition (such as epilepsy) or a significant past head injury
  • People who are currently pregnant
  • People who have taken sedatives or anti-anxiety medications on the day of the assessment
  • People who have had a change in their medication within three weeks before joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 205-934-8205

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 June 2023
Est. completion
1 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Response Bias; the number of optimal response; fMRI activation levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov